Regulatory Briefs: CLIA Update; Product Reclassification; Thrombogenicity Workshop
This article was originally published in The Gray Sheet
FDA provides a Clinical Laboratory Improvement Amendments administrative procedures guidance update. Absorbable lung biopsy plugs are reclassified. FDA will host a public workshop to discuss methods for thrombogenicity testing on April 14.
You may also be interested in...
According to an updated guidance on FDA’s eCopy submission program, it now accepts a broader range of PDFs. The update contains expanded guidelines for industry when submitting electronic versions of applications to FDA.
Final guidelines to companies developing point-of-care diagnostic tests for use in less sophisticated laboratories offer more leeway in clinical trial design than FDA initially proposed
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.